Managing herpes type 1

Antiviral medication is commonly prescribed for patients having a first episode of genital herpes, but they can be used for recurrent episodes as well. There are two kinds of treatment regimens: episodic therapy and suppressive therapy. In this approach, a person begins taking medication at the first sign of an outbreak or ideally at first signs of prodrome and continues taking medication for several days, in order to speed healing or even prevent an outbreak from fully occurring. All three of the antiviral treatments mentioned above have been proven to help shorten the amount of time that a person may experience symptoms of herpes. However, keep in mind that results may vary from person to person.

We are searching data for your request:

Content:

• Clinical management of herpes simplex virus infections: past, present, and future
• Herpes simplex
• Guideline for the Management Herpes Simplex 1 and Cosmetic Interventions
• Herpes simplex - oral
• A home for paediatricians. A voice for children and youth.
• Herpes simplex virus infection
• Newer trends in the management of genital herpes

Clinical management of herpes simplex virus infections: past, present, and future

Herpes simplex virus HSV affects more than one third of the world's population 1 and is responsible for a wide array of human disease, with effects ranging from discomfort to death. Before the s, when acyclovir Zovirax was introduced as an antiviral drug, cutaneous HSV infection was managed with drying agents and other local care. Newer antiviral drugs with once-daily dosage benefits have emerged during the past several years.

Famciclovir Famvir and valacyclovir Valtrex offer effective and convenient therapeutic choices but are often more expensive than acyclovir. HSV is a double-stranded DNA virus that may enter the host through abraded skin or intact mucous membranes. Once infected, these cells die, releasing clear fluid intradermally to form vesicles and merging with other cells to create multinucleated giant cells.

Retrograde transport through adjacent neural tissue to sensory ganglia leads to lifelong latent infection. HSV exists as two separate types, labeled 1 and 2, which have affinities for different body sites. The diagnosis of genital HSV infection may be made clinically, but laboratory confirmation is recommended in patients presenting with primary or suspected recurrent infection.

The gold standard of diagnosis is viral isolation by tissue culture, 1 although this process can take as long as four to five days, and the sensitivity rate is only 70 to 80 percent. Despite these limitations, viral culture is still the diagnostic test of choice for HSV skin infections. Tzanck preparations and antigen detection tests have lower sensitivity rates 50 to 70 percent than viral culture.

Acyclovir, an acyclic guanosine analog, binds viral DNA polymerase, acting as a chain terminator and ending replication. Its mechanism of action necessitates early administration, because replication may end as soon as 48 hours into a recurrence. Oral bioavailability is only 15 to 30 percent; concentrations fold higher can be achieved with intravenous administration.

The drug penetrates well into most body tissues, including the brain, and crosses the placenta. Acyclovir is a safe and extremely well-tolerated drug. Data from more than 35 million patients have been consistent and reassuring. Toxicity is rare, but in patients who are dehydrated or who have poor renal function, the drug can crystallize in the renal tubules, leading to a reversible creatinine elevation or, rarely, acute tubular necrosis.

Adverse effects, usually mild, include nausea, vomiting, rash and headache. Lethargy, tremulousness, seizures and delirium have been reported rarely in studies of renally impaired patients. The Acyclovir in Pregnancy Registry has documented prenatal exposures in more than women with first-trimester exposures without any adverse outcomes. Food and Drug Administration. Valacyclovir, a new antiviral agent, is the l-valine ester prodrug of acyclovir; it is easily absorbed and converted to acyclovir.

It has an oral bioavailability three to five times greater than that of acyclovir, 8 and several large trials have shown that it is safe and well tolerated.

Famciclovir, another new antiviral medication, is the oral form of penciclovir, a purine analog similar to acyclovir. Oral bioavailability is 77 percent, and the drug is quickly converted to its active form. Genital HSV infection is usually transmitted through sexual contact; therefore, it generally does not occur before adolescence.

When genital herpes occurs in a preadolescent, the possibility of abuse must be considered, as with all sexually transmitted diseases in children. Recent evidence indicates that Independent risk factors include multiple sexual partners, increasing age, female gender, low socioeconomic status and human immunodeficiency virus HIV infection.

Primary genital herpes has an incubation period of two to 12 days, with a mean of four days, followed by a prodrome of itching, burning or erythema. In immunocompetent patients, the initial ulceration crusts and heals by 14 to 21 days. Systemic symptoms are common in primary disease and include fever, headache, malaise, abdominal pain and myalgia.

Shedding of viable viral particles happens frequently. Differences in shedding rates between genders have not been identified. Women with established genital HSV-2 infection have asymptomatic shedding 1 to 5 percent of days, 1 and many patients, especially those with recent primary infection or coinfection with HIV, shed virus even more frequently.

Antiviral therapy is recommended for an initial genital herpes outbreak, especially if the patient has systemic symptoms or is immunocompromised. Intravenous administration may be required in immunocompromised patients and those with severe disseminated infection. The oral acyclovir dosage for treatment of primary or initial nonprimary genital herpes is mg five times daily for 10 days.

This regimen does not influence the frequency or number of recurrences. It cannot eradicate latent virus and does not affect the long-term natural history of the infection. Few data are available regarding newer drugs in the treatment of primary disease. Valacyclovir, given twice daily, is indicated for the treatment of primary genital herpes but costs more than acyclovir. There is evidence that famciclovir, given three times daily, is as effective as acyclovir in the treatment of initial genital herpes infection, 20 although it may be twice as expensive Table 2.

Recurrences of herpes are often mild and infrequent, and most patients do not seek treatment. Drug therapy to prevent recurrences is available and effective, but because of cost and inconvenience issues, it is traditionally reserved for use in patients who have more than six outbreaks per year.

Suppressive therapy in these patients is intended to reduce the frequency and severity of herpes symptoms, decrease the transmission of HSV to sexual partners and infants of infected mothers, and decrease the transmission of associated viral diseases i.

Unfortunately, only the first goal has yet proved to be attainable. Acyclovir has been used to suppress recurrences of genital herpes, decreasing the frequency by as much as 80 percent and preventing recurrence by as much as 45 percent of patients.

In addition, cost and compliance should be discussed with the patient. Acyclovir resistance has not been a problem in immunocompetent patients but has been documented in 4 percent of HIV-infected persons. Large, randomized, double-blind trials have shown famciclovir and valacyclovir to be as effective as acyclovir in suppressing recurrent genital herpes 10 , 12 , 13 , 21 Table 3.

Valacyclovir has the advantage of once-daily dosing. Aspirin, in a dosage of mg daily, reduced active-infection days by nearly 50 percent in a small, unblinded pilot study.

Vaccines, which are still in the beginning stages of research, may in the future be capable of reducing the frequency and severity of recurrences. Episodic treatment is intended to diminish symptoms and infectivity during recurrences rather than reduce the frequency of recurrences.

Acyclovir, taken within minutes to hours after the prodrome of recurrence begins, exerts a statistical, albeit minimal benefit in recurrent genital herpes infections. Because the benefit, although statistically significant, is small, many have questioned the clinical usefulness of episodic treatment.

Because the number, severity and personal impact of recurrences vary so greatly, patients should be encouraged to participate in decisions regarding episodic antiviral therapy Table 4. One hope in treating genital herpes is that the rate of shedding and transmission might be influenced, although a link between decreasing viral shedding and decreasing actual transmission has not yet been shown.

Potential preventive strategies are listed in Table 5. Orolabial herpes gingivostomatitis is the most prevalent form of mucocutaneous herpes infection; 35 to 60 percent of white persons in the United States show serologic evidence of having been infected by HSV Overall, the highest rate of infection occurs during the preschool years. Primary herpetic gingivostomatitis usually affects children under the age of five.

It typically takes the form of painful vesicles and ulcerative erosions on the tongue, palate, gingiva, buccal mucosa and lips Figure 2. Edema, halitosis and drooling may be present, and tender submandibular or cervical lymphadenopathy is not uncommon. Systemic symptoms are often present, including fever The pharyngitis and flu-like symptoms are difficult to distinguish from mononucleosis in older patients.

The duration of the illness is two to three weeks, and oral shedding of virus may continue for as long as 23 days. Recurrences typically occur two or three times a year. The duration is shorter and the discomfort less severe than in primary infections; the lesions are often single and more localized, and the vesicles heal completely by eight to 10 days.

Pain diminishes quickly in four to five days. UV radiation predictably triggers recurrence of orolabial HSV-1, an effect which, for unknown reasons, is not fully suppressed by acyclovir.

Topical medication for HSV infection is generally not highly effective. Topical acyclovir has not proved to accelerate healing. Topical penciclovir, applied every two hours for four days, reduces clinical healing time by only about one day. In the treatment of primary orolabial herpes, oral acyclovir, in a dosage of mg five times daily for five days, accelerates loss of crusts by one day seven versus eight days in adults 1 and can reduce the mean duration of pain by 36 percent. In one study involving children up to six years of age, acyclovir, in a dosage of 15 mg per kg five times daily for seven days, decreased the duration of oral lesions in primary infection from 10 days to four days, shortened viral shedding and reduced the duration of eating difficulties from seven days to four days.

Evidence from clinical trials of the newer antiviral agents as therapy for orolabial herpes is currently lacking. Although long-term suppression of orolabial herpes has not been addressed by clinical trials, episodic prophylaxis has been studied because of the predictable trigger effect of UV radiation. A recent review 37 found no evidence that topical acyclovir was helpful in preventing recurrence secondary to UV light exposure. Oral acyclovir, however, in dosages ranging from to 1, mg daily, was effective in reducing by 50 to 78 percent the frequency of herpes labialis following UV light exposure.

In another study involving skiers, 38 oral acyclovir did not decrease the recurrence rate but lessened the severity of lesions when they occurred.

Short-term prophylactic therapy with acyclovir, therefore, may be desirable in some patients who anticipate intense exposure to UV light e. Early treatment of recurrent orolabial HSV infection with high dosages of antiviral medication has recently been found to markedly decrease the size and duration of lesions. Famciclovir, in a dosage of mg three times daily for five days, decreased mean lesion surface area by more than 50 percent and accelerated healing time from 5.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.

The Virus and Pathogenesis. Antiviral Medications. Genital Herpes. A typical genital herpes lesion. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. Montvale, N. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women.

A multicenter, double-blind, placebo-controlled trial.

Herpes simplex

Genital herpes is the most common cause of ulcerative sexually transmitted infection in the world. The most important aspect of the management revolves around the judicious use of antiviral agents. Many patients with genital herpes may have atypical manifestations. Investigations should be routinely utilized to improve the diagnostic accuracy of genital herpes.

Guideline for the Management Herpes Simplex 1 and Cosmetic Interventions

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy. Human herpes simplex virus HSV infection in neonates can result in devastating outcomes, including mortality and significant morbidity. All infants are potentially at risk for neonatal HSV infection. This position statement reviews epidemiology, transmission and risk factors, with a focus on intrapartum infection. It considers diagnosis and prognosis according to infection category, along with testing modalities and limitations. Recommendations for managing newborns known to have been exposed intrapartum to HSV are based on expert opinion because a randomized trial to compare management options is not feasible.

Herpes simplex - oral

This common STI may be transmitted to newborns during delivery; however, early recognition and treatment will improve outcomes. The authors stress the importance of detection, as many cases may be asymptomatic. A year-old primigravid woman at 12 weeks of gestation indicates that she had an initial episode of herpes simplex virus HSV 6 years prior to presentation. Subsequently, she has had 1 to 2 recurrent episodes each year. She asks about the implications of HSV infection in pregnancy, particularly if anything can be done to prevent a recurrent outbreak near her due date and reduce the need for a cesarean delivery.

A home for paediatricians. A voice for children and youth.

Error: This is required. Error: Not a valid value. Genital herpes is a sexually transmitted infection that is caused by the herpes simplex virus HSV — the same type of virus that causes cold sores. Genital herpes can cause outbreaks of blisters or sores on the genitals and anus. Once infected, you can continue to have episodes of symptoms throughout your life.

Herpes simplex virus infection

When checking for signs of skin cancer, you may only think to check your skin. However, it's important to check your nails, too. Dermatologists are the experts when it comes to treating acne. If you have acne, a board-certified dermatologist can help. Everyone's at risk for skin cancer. These dermatologists' tips tell you how to protect your skin. Causing deep and painful lumps under the skin, usually in the armpits or groin, this disease often worsens without proper treatment. You can expect permanent results in all but one area.

Newer trends in the management of genital herpes

An estimated 3. Although the acute stage of these conditions is usually short, there may be long-lasting debilitating complications. For example, acute herpetic gingivostomatitis lasts days, but the symptoms of pain, myalgia, etc. In this scenario, arresting the viral replication in the early phase of the disease has been shown to achieve earlier recovery and prevention from the long-term sequel.

Genital herpes, caused by herpes simplex virus HSV type 1 or type 2, is a prevalent sexually transmitted infection STI. Given that HSV is an incurable infection, there are important concerns about appropriate use of diagnostic tools, management of infection, prevention of transmission to sexual partners, and appropriate counseling. In preparation for updating the Centers for Disease Control and Prevention CDC STI treatment guidelines, key questions for management of genital herpes infection were developed with a panel of experts. To answer these questions, a systematic literature review was performed, with tables of evidence including articles that would change guidance assembled. Genital herpes is a chronic sexually transmitted infection STI characterized by recurrent, self-limited genital ulcers, caused by herpes simplex virus type 1 HSV-1 or type 2 HSV

DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages. Home arrow-right-small-blue Topics A—Z arrow-right-small-blue Herpes simplex. Updated October Herpes simplex is a common viral infection that presents with localised blistering.

Orolabial herpes commonly known as cold sores or fever blisters is the most common manifestation of HSV-1 infection. Classic manifestations of oral HSV-1 include a sensory prodrome in the affected area, rapidly followed by lesions on lips and oral mucosa that evolve in stages from papule to vesicle, ulcer, and crust. The course of illness in untreated patients is 5 days to 10 days. Lesions recur 1 to 12 times per year and can be triggered by sunlight or physiologic stress.